Sleep Apnea Devices: The Changing Of The Guard
This article was originally published in Start Up
The current specialty-dominated care paradigm for sleep apnea can't scale-up to meet the demands of an enormous and serious chronic disease. New companies help move diagnosis and treatment to the physicians that see patients first.
You may also be interested in...
Sorin’s $20 million investment will help Respicardia continue the U.S. pivotal trial of the remedē implantable phrenic nerve stimulator for sleep apnea and give Sorin exclusive rights to distribute the device in select European countries, where it has a CE mark but has yet to be launched.
Sleep apnea is now widely recognized as an underlying factor for major CV diseases and metabolic disorders, making it a huge market opportunity. ApniCure hopes that by avoiding the CPAP masks that patients hate while using the differential pressure therapy that doctors and payors like, it can unlock this potential blockbuster market.
The drive toward cost-effectiveness and expanded patient access have spurred device developers to take proven therapies or procedures and re-engineer them in ways that make them simpler, less expensive and easier to use. Now, the biggest player in wound care is following suit. In January, Smith & Nephew PLC announced that the FDA had cleared PICO, its new, single-use, pocket-sized negative pressure wound therapy (NPWT) system.